Is it time to reconsider initial antibiotic treatment strategies for severe urinary tract infections in Europe?

Clinical Microbiology and Infection

Volumn 13, Issue 3, 2007, Pages 219-221

  Zahar, J R ^a   Lecuit, M ^a   Carbonnelle, E ^a   Ribadeau dumas, F ^a   Nassif, X ^a   Lortholary, O ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Antibiotic therapy; Bacteraemia; Extended spectrum lactamase; Geographical origin; Risk factor; Urinary tract infection

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFOTAXIME; CEPHALOSPORIN; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DIVERTICULITIS; DRUG SUBSTITUTION; EDITORIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; RISK FACTOR; TRAVEL; URINARY TRACT INFECTION;

EID: 34247212913     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01666.x     Document Type: Editorial

References (10)

1. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
2. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352: 380-391.
3. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
4. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
5. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA. Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis 2004; 190: 1739-1744.
6. Moubareck C, Daoud Z, Hakime NI et al. Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol 2005; 43: 3309-3313.
7. Daoud Z, Hakime N. Prevalence and susceptibility patterns of extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in a general university hospital in Beirut, Lebanon. Rev Esp Quimioter 2003; 16: 233-238.
8. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42: 925-934.
9. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 2003; 9: 1024-1025.
10. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163-167.